Real-World Treatment Pathways of Adult Patients with Glioblastoma and Other CNS Tumors: A Population-Based Registry Study
Authors:
- Eliana FerroniEFEliana Ferroni
- Alessandra AndreottiAAAlessandra Andreotti
- Stefano GuzzinatiSGStefano Guzzinati
- Susanna BaraccoSBSusanna Baracco
- Maddalena BaraccoMBMaddalena Baracco
- Emanuela BovoEBEmanuela Bovo
- Eva CarpinECEva Carpin
- Antonella Dal CinACAntonella Dal Cin
- Alessandra GrecoAGAlessandra Greco
- Anna Rita FioreAFAnna Rita Fiore
- Laura MemoLMLaura Memo
- Daniele MonettiDMDaniele Monetti
Open Access
- 21 April 2026
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 33 (4) , 236
Abstract
Background: Population-level evidence on delivery of neuro-oncology care is essential for evaluating access, equity, and quality of treatment pathways. However, real-world data describing how patients with central nervous system (CNS) tumors, especially with glioblastoma, are managed across healthcare systems remain limited. This study aimed to characterize treatment pathways using linked registry and administrative data within a regional care network. Methods: All adult CNS tumors diagnosed between 2016 and 2020 were identified in the Veneto Cancer Registry. Tumor grading was derived using a validated text-mining algorithm, and surgical, radiotherapy, and systemic treatments were captured through linkage with regional healthcare utilization databases. Patterns of care were evaluated by tumor subtype, grade, and diagnostic pathway. Results: Among 1634 histologically confirmed tumors, glioblastoma represented the largest group. Surgical intervention was widely implemented, with high resection rates in glioblastoma and meningioma. Combined chemoradiotherapy constituted the primary adjuvant approach for glioblastoma and high-grade diffuse gliomas, whereas management of lower-grade tumors showed greater variability. Approximately one-third of patients received no oncologic therapy, primarily associated with older age or diagnostic uncertainty. Analysis of recurrent glioblastoma showed heterogeneous systemic treatment use, reflecting evolving therapeutic practice. Conclusions: Linking population-based registry and administrative data provides actionable insight into real-world delivery of neuro-oncology care, in particular for glioblastoma patients. This approach enables monitoring of treatment variability, identification of potential access gaps, and evaluation of system-level performance, supporting data-driven planning of multidisciplinary services and future quality improvement initiatives.Keywords
All Related Versions
Funding Information
- Ministero della Salute (L03P03)
This publication has 20 references indexed in Scilit:
- Incidence and survival of adult central nervous system tumors in the Veneto region: a population-based registry study (2016–2020)Journal of Neuro-Oncology, 2025
- Primary brain tumours in adultsThe Lancet, 2018
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomasThe Lancet Oncology, 2017
- Short-Course Radiation plus Temozolomide in Elderly Patients with GlioblastomaNew England Journal of Medicine, 2017
- Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyThe Lancet Oncology, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Epidemiology of glial and non-glial brain tumours in EuropeEuropean Journal of Cancer, 2012
- Conditional probability of long‐term survival in glioblastomaCancer, 2012
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- The treatment of adults with medulloblastoma: a prospective studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003